Market Closed -
Hong Kong S.E.
09:08:20 14/05/2024 BST
|
5-day change
|
1st Jan Change
|
4.99
HKD
|
-1.38%
|
|
+11.38%
|
+22.00%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
11,223
|
14,321
|
24,421
|
22,930
|
16,225
|
17,474
|
17,474
|
-
|
Enterprise Value (EV)
1 |
11,223
|
14,321
|
24,421
|
22,930
|
16,225
|
14,394
|
17,474
|
17,474
|
P/E ratio
|
-
|
-
|
-
|
-
|
-
|
7.63
x
|
7.33
x
|
6.33
x
|
Yield
|
-
|
-
|
-
|
-
|
3.04%
|
6.36%
|
2.57%
|
3.16%
|
Capitalization / Revenue
|
1.88
x
|
2.17
x
|
3.84
x
|
2.67
x
|
1.7
x
|
1.37
x
|
1.45
x
|
1.28
x
|
EV / Revenue
|
1.88
x
|
2.17
x
|
3.84
x
|
2.67
x
|
1.7
x
|
1.37
x
|
1.45
x
|
1.28
x
|
EV / EBITDA
|
-
|
-
|
10,116,064
x
|
7,124,918
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
14.9
x
|
13.3
x
|
7.54
x
|
10.6
x
|
8.5
x
|
FCF Yield
|
-
|
-
|
-
|
6.69%
|
7.5%
|
13.3%
|
9.43%
|
11.8%
|
Price to Book
|
-
|
-
|
-
|
1.71
x
|
1.14
x
|
0.94
x
|
1.01
x
|
0.89
x
|
Nbr of stocks (in thousands)
|
3,134,826
|
3,377,571
|
3,549,571
|
3,549,571
|
3,527,141
|
3,501,810
|
3,501,810
|
-
|
Reference price
2 |
3.580
|
4.240
|
6.880
|
6.460
|
4.600
|
5.060
|
5.060
|
5.060
|
Announcement Date
|
26/03/19
|
27/03/20
|
28/04/21
|
17/03/22
|
22/03/23
|
19/03/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
5,958
|
6,591
|
6,353
|
8,598
|
9,562
|
10,530
|
12,055
|
13,620
|
EBITDA
|
-
|
-
|
2,414
|
3,218
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
1,383
|
2,127
|
2,879
|
2,654
|
2,549
|
3,205
|
3,681
|
Operating Margin
|
-
|
20.98%
|
33.48%
|
33.48%
|
27.76%
|
24.21%
|
26.59%
|
27.03%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-
|
-
|
-
|
2,344
|
2,988
|
3,463
|
Net income
1 |
-
|
-
|
-
|
-
|
-
|
1,880
|
2,445
|
2,835
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
17.85%
|
20.28%
|
20.81%
|
EPS
2 |
-
|
-
|
-
|
-
|
-
|
0.5360
|
0.6900
|
0.8000
|
Free Cash Flow
1 |
-
|
-
|
-
|
1,534
|
1,216
|
2,317
|
1,648
|
2,056
|
FCF margin
|
-
|
-
|
-
|
17.84%
|
12.72%
|
21.85%
|
13.67%
|
15.1%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
47.67%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
109.04%
|
67.4%
|
72.52%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
0.1400
|
0.2600
|
0.1300
|
0.1600
|
Announcement Date
|
26/03/19
|
27/03/20
|
28/04/21
|
17/03/22
|
22/03/23
|
19/03/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
1,534
|
1,216
|
2,317
|
1,648
|
2,056
|
ROE (net income / shareholders' equity)
|
-
|
-
|
18.3%
|
19.5%
|
15.1%
|
12.8%
|
14%
|
14%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
11.6%
|
12.6%
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
3.770
|
4.020
|
4.330
|
5.030
|
5.670
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
373
|
566
|
209
|
472
|
626
|
600
|
800
|
1,000
|
Capex / Sales
|
6.26%
|
8.59%
|
3.29%
|
5.48%
|
6.55%
|
5.66%
|
6.64%
|
7.34%
|
Announcement Date
|
26/03/19
|
27/03/20
|
28/04/21
|
17/03/22
|
22/03/23
|
19/03/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +22.00% | 2.27B | | +29.62% | 682B | | +30.35% | 586B | | -3.77% | 364B | | +17.52% | 327B | | +3.31% | 285B | | +15.53% | 240B | | +10.16% | 209B | | -8.14% | 203B | | +7.20% | 165B |
Other Pharmaceuticals
|